Edwards Lifesciences Corp. (NYSE:EW) VP Huimin Wang sold 13,650 shares of Edwards Lifesciences Corp. stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $120.04, for a total transaction of $1,638,546.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Huimin Wang also recently made the following trade(s):

  • On Tuesday, September 6th, Huimin Wang sold 13,650 shares of Edwards Lifesciences Corp. stock. The stock was sold at an average price of $115.72, for a total transaction of $1,579,578.00.
  • On Friday, August 5th, Huimin Wang sold 13,650 shares of Edwards Lifesciences Corp. stock. The stock was sold at an average price of $113.03, for a total transaction of $1,542,859.50.

Edwards Lifesciences Corp. (NYSE:EW) opened at 120.09 on Monday. The company has a market capitalization of $25.56 billion, a price-to-earnings ratio of 49.62 and a beta of 0.56. Edwards Lifesciences Corp. has a 52-week low of $71.93 and a 52-week high of $121.73. The firm has a 50 day moving average of $117.50 and a 200-day moving average of $107.22.

Edwards Lifesciences Corp. (NYSE:EW) last released its earnings results on Tuesday, July 26th. The medical research company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.70 by $0.06. The company earned $759.30 million during the quarter, compared to analysts’ expectations of $724.26 million. Edwards Lifesciences Corp. had a net margin of 19.26% and a return on equity of 23.72%. Edwards Lifesciences Corp.’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same period last year, the business earned $0.57 EPS. Equities analysts expect that Edwards Lifesciences Corp. will post $2.88 EPS for the current year.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corp. (NYSE:EW)

A number of brokerages have issued reports on EW. Deutsche Bank AG raised their price target on shares of Edwards Lifesciences Corp. from $100.00 to $115.00 and gave the stock a “hold” rating in a report on Wednesday, July 27th. Morgan Stanley lifted their target price on shares of Edwards Lifesciences Corp. from $110.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, July 27th. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $130.00 target price on shares of Edwards Lifesciences Corp. in a research note on Thursday, July 28th. Canaccord Genuity lifted their target price on shares of Edwards Lifesciences Corp. from $132.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, July 27th. Finally, Zacks Investment Research lowered shares of Edwards Lifesciences Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $118.13.

A number of hedge funds have recently added to or reduced their stakes in EW. Vanguard Group Inc. boosted its stake in Edwards Lifesciences Corp. by 0.7% in the second quarter. Vanguard Group Inc. now owns 18,796,184 shares of the medical research company’s stock worth $1,874,543,000 after buying an additional 134,432 shares during the period. FMR LLC boosted its stake in Edwards Lifesciences Corp. by 1.2% in the second quarter. FMR LLC now owns 12,366,588 shares of the medical research company’s stock worth $1,233,319,000 after buying an additional 141,713 shares during the period. BlackRock Institutional Trust Company N.A. boosted its stake in Edwards Lifesciences Corp. by 0.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 5,451,618 shares of the medical research company’s stock worth $480,887,000 after buying an additional 14,400 shares during the period. Ameriprise Financial Inc. boosted its stake in Edwards Lifesciences Corp. by 62.3% in the second quarter. Ameriprise Financial Inc. now owns 4,253,976 shares of the medical research company’s stock worth $424,200,000 after buying an additional 1,632,567 shares during the period. Finally, BlackRock Fund Advisors boosted its stake in Edwards Lifesciences Corp. by 4.6% in the second quarter. BlackRock Fund Advisors now owns 4,194,236 shares of the medical research company’s stock worth $418,291,000 after buying an additional 184,872 shares during the period. Institutional investors own 84.09% of the company’s stock.

About Edwards Lifesciences Corp.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Receive News & Stock Ratings for Edwards Lifesciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp. and related stocks with our FREE daily email newsletter.